These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 852495)

  • 1. Elimination of canrenone in congestive heart failure and chronic liver disease.
    Jackson L; Branch R; Levine D; Ramsay L
    Eur J Clin Pharmacol; 1977 Mar; 11(3):177-9. PubMed ID: 852495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of spironolactone and its metabolite canrenone on serum digoxin assays.
    Foukaridis GN
    Ther Drug Monit; 1990 Jan; 12(1):82-4. PubMed ID: 2305425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels.
    Karim A; Zagarella J; Hutsell TC; Dooley M
    Clin Pharmacol Ther; 1976 Feb; 19(2):177-82. PubMed ID: 1261155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement by food of canrenone bioavailability from spironolactone.
    Melander A; Danielson K; Scherstén B; Thulin T; Wåhlin E
    Clin Pharmacol Ther; 1977 Jul; 22(1):100-3. PubMed ID: 872489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitation of spironolactone and its metabolite, canrenone, in human serum by thin-layer spectrofluorimetry.
    van der Merwe PJ; Müller DG; Clark EC
    J Chromatogr; 1979 Apr; 171():519-21. PubMed ID: 546864
    [No Abstract]   [Full Text] [Related]  

  • 7. Spironolactone response related to plasma canrenone concentration [proceedings].
    Hettiarachchi J; Ramsay LE
    Br J Clin Pharmacol; 1979 Apr; 7(4):426P-427P. PubMed ID: 444376
    [No Abstract]   [Full Text] [Related]  

  • 8. High-performance liquid chromatographic determination of canrenone, a major metabolite of spironolactone, in body fluids.
    Neurath GB; Ambrosius D
    J Chromatogr; 1979 Jun; 163(2):230-5. PubMed ID: 541378
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple dose kinetics of spironolactone and canrenoate-potassium in cardiac and hepatic failure.
    Sadée W; Schröder R; von Leitner E; Dagcioglu M
    Eur J Clin Pharmacol; 1974; 7(3):195-200. PubMed ID: 4853286
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics of canrenone and metabolites after base hydrolysis following single and multiple dose oral administration of spironolactone.
    Ho PC; Bourne DW; Triggs EJ; Heazlewood V
    Eur J Clin Pharmacol; 1984; 27(4):441-6. PubMed ID: 6519151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
    Merkus FW; Overdiek JW; Cilissen J; Zuidema J
    Clin Exp Hypertens A; 1983; 5(2):239-48. PubMed ID: 6831747
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of plasma levels of canrenone and metabolites after base hydrolysis in young and elderly subjects following single and multiple doses of spironolactone.
    Ho PC; Bourne DW; Triggs EJ; Smithurst BA
    Eur J Clin Pharmacol; 1984; 27(4):435-9. PubMed ID: 6519150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-interaction of spironolactone medication and cortisol metabolism in man.
    Abshagen U; Spörl S; L'age M
    Klin Wochenschr; 1978 Feb; 56(3):135-8. PubMed ID: 628197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk.
    Phelps DL; Karim A
    J Pharm Sci; 1977 Aug; 66(8):1203. PubMed ID: 894512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of canrenone, the major metabolite of spironolactone, in plasma and urine by high-performance liquid chromatography.
    Krause W; Karras J; Jakobs U
    J Chromatogr; 1983 Oct; 277():191-9. PubMed ID: 6643605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relative bioavailability in man of 2 pharmaceutical forms of canrenone].
    Bressolle F; Bres J; Faure A; Pistre MC
    Eur J Drug Metab Pharmacokinet; 1986; 11(3):165-70. PubMed ID: 3816872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is canrenone the major metabolite of spironolactone?
    Merkus FW
    Clin Pharm; 1983; 2(3):209-10. PubMed ID: 6883952
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of single and divided daily dose spironolactone in the control of hypertension.
    Bell GM; Fananapazir L; Anderton JL
    Br J Clin Pharmacol; 1981 Oct; 12(4):585-8. PubMed ID: 7295494
    [No Abstract]   [Full Text] [Related]  

  • 20. Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation.
    de Denus S; O'Meara E; Desai AS; Claggett B; Lewis EF; Leclair G; Jutras M; Lavoie J; Solomon SD; Pitt B; Pfeffer MA; Rouleau JL
    N Engl J Med; 2017 Apr; 376(17):1690-1692. PubMed ID: 28445660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.